Published in Pharmacotherapy on December 01, 2012
Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma | NCT00556205
Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res (2014) 1.54
The Role of Mast Cell Specific Chymases and Tryptases in Tumor Angiogenesis. Biomed Res Int (2015) 0.91
Computational systems biology approaches to anti-angiogenic cancer therapeutics. Drug Discov Today (2014) 0.90
Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation. Chin J Cancer (2016) 0.88
Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization. J Cell Mol Med (2014) 0.86
Suppression of interactions between prostate tumor cell-surface integrin and endothelial ICAM-1 by simvastatin inhibits micrometastasis. J Cell Physiol (2013) 0.85
Antiangiogenic cancer treatment: The great discovery and greater complexity (Review). Int J Oncol (2016) 0.83
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer (2016) 0.82
Ovatodiolide Targets β -Catenin Signaling in Suppressing Tumorigenesis and Overcoming Drug Resistance in Renal Cell Carcinoma. Evid Based Complement Alternat Med (2013) 0.82
Can oncology recapitulate paleontology? Lessons from species extinctions. Nat Rev Clin Oncol (2015) 0.82
GDNF secreted from adipose-derived stem cells stimulates VEGF-independent angiogenesis. Oncotarget (2016) 0.80
Imaging biomarkers in primary brain tumours. Eur J Nucl Med Mol Imaging (2014) 0.80
The Contribution of Angiogenesis to the Process of Metastasis. Cancer J (2015) 0.80
Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. Cancer Lett (2014) 0.80
Antiangiogenic Effect of Ethanol Extract of Vigna angularis via Inhibition of Phosphorylation of VEGFR2, Erk, and Akt. Evid Based Complement Alternat Med (2015) 0.80
Adeno-associated virus (AAV) vectors in cancer gene therapy. J Control Release (2016) 0.80
Profile of nintedanib in the treatment of solid tumors: the evidence to date. Onco Targets Ther (2015) 0.78
Plants and their active compounds: natural molecules to target angiogenesis. Angiogenesis (2016) 0.77
MiR-199a inhibits the angiogenic potential of endometrial stromal cells under hypoxia by targeting HIF-1α/VEGF pathway. Int J Clin Exp Pathol (2015) 0.77
Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next? Clin Med Insights Oncol (2016) 0.76
Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date. Onco Targets Ther (2017) 0.75
Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions. Cancers (Basel) (2017) 0.75
High-precision, non-invasive anti-microvascular approach via concurrent ultrasound and laser irradiation. Sci Rep (2017) 0.75
Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts. Oncol Rep (2016) 0.75
Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells. Oncol Lett (2014) 0.75
Structure-Activity Relationship of Indole-Tethered Pyrimidine Derivatives that Concurrently Inhibit Epidermal Growth Factor Receptor and Other Angiokinases. PLoS One (2015) 0.75
Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer. Oncol Ther (2016) 0.75
Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy. Int J Mol Sci (2017) 0.75
Pediatric Osteosarcoma: An Updated Review. Indian J Med Paediatr Oncol (2017) 0.75
Modeling tumor cell adaptations to hypoxia in multicellular tumor spheroids. J Exp Clin Cancer Res (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A (1995) 24.77
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
Angiogenesis in life, disease and medicine. Nature (2005) 15.36
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science (1994) 12.83
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Angiogenesis as a therapeutic target. Nature (2005) 11.89
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
Tumor angiogenesis. N Engl J Med (2008) 11.30
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2004) 10.55
Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science (1997) 10.54
Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med (2011) 8.93
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol (2008) 8.79
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol (2009) 7.80
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun (1989) 7.39
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol (2011) 6.18
Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest (2006) 6.12
Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev (1994) 5.66
Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol (2001) 5.17
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell (2007) 5.09
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol (2010) 5.08
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol (2010) 5.01
Ligand binding to integrins. J Biol Chem (2000) 4.94
Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature (2010) 4.85
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol (2010) 4.81
Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem (1997) 4.43
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2008) 4.29
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol (2005) 4.02
Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene. Development (1996) 3.84
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol (2012) 3.73
Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest (1995) 3.69
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 3.65
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol (2010) 3.40
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol (2009) 3.28
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol (2005) 3.28
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.13
Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res (2008) 2.98
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol (2008) 2.59
An essential role for ARF6-regulated membrane traffic in adherens junction turnover and epithelial cell migration. EMBO J (2001) 2.50
Interference with netrin-1 and tumor cell death in non-small cell lung cancer. J Natl Cancer Inst (2009) 2.16
Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res (2003) 2.15
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther (2008) 1.96
Heparan sulfate proteoglycan syndecan promotes axonal and myotube guidance by slit/robo signaling. Curr Biol (2004) 1.93
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol (2009) 1.88
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.71
The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc Med (2002) 1.70
Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol (1996) 1.53
Cancer research. Mutant stem cells may seed cancer. Science (2003) 1.50
Quantification of expression of netrins, slits and their receptors in human prostate tumors. Int J Cancer (2003) 1.45
Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res (2003) 1.41
Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer (2003) 1.40
Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands. Mol Cell (2010) 1.39
[Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]. Zhongguo Fei Ai Za Zhi (2005) 1.38
Integrin and growth factor receptor alliance in angiogenesis. Cell Biochem Biophys (2008) 1.31
A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol (2011) 1.25
Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res (2010) 1.18
Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer (2012) 1.17
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol (2010) 1.16
Notch signalling in cancer progression and bone metastasis. Br J Cancer (2011) 1.09
Netrin-1 and its dependence receptors as original targets for cancer therapy. Curr Opin Oncol (2010) 1.04
RGD-recognizing integrins mediate interactions of human prostate carcinoma cells with endothelial cells in vitro. Prostate (1999) 1.04
Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood (2011) 1.00
Endothelin-induced apoptosis of A375 human melanoma cells. J Biol Chem (1998) 1.00
Robo4-dependent Slit signaling stabilizes the vasculature during pathologic angiogenesis and cytokine storm. Curr Opin Hematol (2011) 0.97
Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett (2004) 0.95
Antiangiogenic agents and targets: A perspective. Biochem Pharmacol (2010) 0.92
Angiogenesis inhibitors in the treatment of prostate cancer. J Hematol Oncol (2010) 0.91
Targeting the endothelin system: novel therapeutic options in gynecological, urological and breast cancers. Expert Rev Anticancer Ther (2008) 0.91
Endothelins and their receptors in cancer: identification of therapeutic targets. Pharmacol Res (2011) 0.85
Bone marrow-derived endothelial progenitors expressing Delta-like 4 (Dll4) regulate tumor angiogenesis. PLoS One (2011) 0.83
The role of Ang/Tie signaling in lymphangiogenesis. Lymphology (2010) 0.81
Erythropoietin disrupts hypoxia-inducible factor signaling in ovarian cancer cells. Gynecol Oncol (2005) 0.81
Target inhibition in antiangiogenic therapy a wide spectrum of selectivity and specificity. Cancer J (2010) 0.80
Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med (2005) 3.60
PAK1 as a therapeutic target. Expert Opin Ther Targets (2010) 1.48
Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J Pharmacol Exp Ther (2010) 1.31
Integrin affinity modulation in angiogenesis. Cell Cycle (2007) 1.17
The angiogenic response is dictated by beta3 integrin on bone marrow-derived cells. J Cell Biol (2008) 1.11
Vascular protection by angiotensin receptor antagonism involves differential VEGF expression in both hemispheres after experimental stroke. PLoS One (2011) 1.10
PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer. Int J Oncol (2011) 1.09
TGFβ- and bleomycin-induced extracellular matrix synthesis is mediated through Akt and mammalian target of rapamycin (mTOR). J Cell Physiol (2011) 1.09
P21 activated kinase-1 (Pak1) promotes prostate tumor growth and microinvasion via inhibition of transforming growth factor β expression and enhanced matrix metalloproteinase 9 secretion. J Biol Chem (2012) 1.07
Methods for isolation of endothelial and smooth muscle cells and in vitro proliferation assays. Methods Mol Med (2006) 1.07
Cerebrovascular complications of diabetes: focus on stroke. Endocr Metab Immune Disord Drug Targets (2012) 1.04
TGFβ1 induces apoptosis in invasive prostate cancer and bladder cancer cells via Akt-independent, p38 MAPK and JNK/SAPK-mediated activation of caspases. Biochem Biophys Res Commun (2012) 1.03
Enhanced cerebral but not peripheral angiogenesis in the Goto-Kakizaki model of type 2 diabetes involves VEGF and peroxynitrite signaling. Diabetes (2012) 1.02
Diverse effects of statins on angiogenesis: new therapeutic avenues. Pharmacotherapy (2010) 1.01
Rac1 activation driven by 14-3-3ζ dimerization promotes prostate cancer cell-matrix interactions, motility and transendothelial migration. PLoS One (2012) 1.01
Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis. BMC Cancer (2012) 0.99
Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence. Clin Sci (Lond) (2011) 0.99
Binding and inactivation of the germ cell-specific protein phosphatase PP1gamma2 by sds22 during epididymal sperm maturation. Biol Reprod (2003) 0.91
Candesartan induces a prolonged proangiogenic effect and augments endothelium-mediated neuroprotection after oxygen and glucose deprivation: role of vascular endothelial growth factors A and B. J Pharmacol Exp Ther (2014) 0.90
Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo. Oncotarget (2014) 0.89
Akt1 mediates α-smooth muscle actin expression and myofibroblast differentiation via myocardin and serum response factor. J Biol Chem (2013) 0.88
Changes in intracellular distribution and activity of protein phosphatase PP1gamma2 and its regulating proteins in spermatozoa lacking AKAP4. Biol Reprod (2004) 0.87
Interference with akt signaling protects against myocardial infarction and death by limiting the consequences of oxidative stress. Sci Signal (2013) 0.86
Suppression of interactions between prostate tumor cell-surface integrin and endothelial ICAM-1 by simvastatin inhibits micrometastasis. J Cell Physiol (2013) 0.85
Identification of chloride intracellular channel proteins in spermatozoa. FEBS Lett (2004) 0.83
TNFα induces inflammatory stress response in microvascular endothelial cells via Akt- and P38 MAP kinase-mediated thrombospondin-1 expression. Mol Cell Biochem (2015) 0.81
Pentoxifylline and local honey for radiation-induced burn following breast conservative surgery. Curr Clin Pharmacol (2010) 0.75
Nonprescription medication use and literacy among New Hampshire eighth graders. J Am Pharm Assoc (2003) (2012) 0.75
Anticancer activity of novel unnatural synthetic isoprenoids. Anticancer Res (2010) 0.75